NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Semler Scientific Inc. (“Semler” or the “Company”) (NASDAQ: SMLR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Semler and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Februar ...

Company Overview - Semler Scientific, Inc. is a healthcare technology company focused on developing and marketing products for the early detection and management of chronic diseases, particularly through its flagship vascular testing device, QuantaFlo [3]. Allegations and Impact - On February 28, 2025, Semler filed its 2024 annual report with the SEC, revealing that the Department of Justice was considering a False Claims Act complaint regarding insurance reimbursement claims related to the QuantaFlo testing device [4]. - Following this disclosure, Semler's stock price dropped by $4.03 per share, representing a decline of 9.4%, closing at $38.89 per share on March 3, 2025 [4]. Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Semler, stemming from allegations of providing potentially misleading business information to investors [1].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Semler Scientific, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Semler Scientific securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Disclosure and Market Reaction - Semler Scientific filed its 2024 annual report on Form 10-K with the SEC, revealing that it had begun initial settlement discussions with the DOJ but ceased those discussions on February 11, 2025 [3]. - Following this disclosure, Semler Scientific's stock fell over 9% on the next trading day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Semler Scientific Inc. and its officers or directors [1] Company Summary - Semler Scientific Inc. filed its annual report for 2024 on February 28, 2025, indicating a risk of a civil complaint from the U.S. Department of Justice related to the False Claims Act [3] - The company received an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3] - Settlement discussions with the DOJ in February 2025 were unsuccessful [3] Market Reaction - Following the news of the investigation and potential legal issues, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

NEW YORK, May 30, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Semler Scientific, Inc. (NASDAQ: SMLR) resulting from allegations that Semler Scientific may have issued materially misleading business information to the investing public.So What: If you purchased Semler Scientific securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conting ...

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. ("Semler" or the "Company") (NASDAQ: SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Semler and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On February 28, 2025, Semler filed its annual report for 2024, in which it ...

Core Viewpoint - Semler Scientific Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, particularly concerning its QuantaFlo device reimbursement claims [1][2]. Company Summary - Semler filed its Form 10-K with the SEC on February 28, 2025, revealing an initial civil investigative demand from the U.S. Department of Justice (DOJ) dating back to July 2017 [2]. - The company has faced multiple requests for information from the DOJ, with significant dates including February 2019, December 2021, April 2022, and April 2023 [2]. - Settlement discussions with the DOJ in February 2025 were unsuccessful, leading to concerns that the DOJ may file a civil False Claims Act lawsuit against Semler [2]. - Following the news of the investigation, Semler's share price dropped from $42.92 to $38.89, a decline of $4.03 per share, between February 28 and March 3, 2025 [2]. Legal Context - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Semler stockholders regarding the company's legal issues [1]. - The law firm specializes in representing investors in complex litigation, including securities and derivative cases [4].

Core Viewpoint - Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential breaches of fiduciary duty by the Board of Directors and senior management of Semler Scientific Inc. related to securities fraud allegations [1][2]. Investigation Details - The investigation focuses on whether certain officers and/or directors of Semler have engaged in securities fraud [2]. - Semler disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 regarding claims for reimbursement related to the QuantaFlo device [3]. - Subsequent requests for information from the DOJ occurred in February 2019, December 2021, April 2022, and April 2023, with unsuccessful settlement discussions taking place in February 2025 [3]. - There is a risk that the DOJ may file a complaint in a civil False Claims Act lawsuit seeking damages against Semler [3]. Firm Background - Wolf Haldenstein has extensive experience in prosecuting securities class actions and derivative litigation across state and federal courts [3]. - The firm is recognized for its expertise in shareholder and class litigation, having been appointed to significant positions in complex securities and multi-district litigation by the courts [3].

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Semler Scientific Inc., (NASDAQ: SMLR) (“Semler” or the “Company”). The investigation concerns whether and certain of its officers and/or directors have engaged in securit ...

Semler Scientific (SMLR) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Douglas Murphy-Chutorian - CEOEric Semler - ChairmanJennifer Herrington - Chief Operating OfficerRenae Cormier - CFO Operator Good afternoon, and welcome to the Semler Scientific First Quarter twenty twenty five Financial Results Conference Call. All participants will be in a listen only mode. After today's prepared remarks, as time permits, management will take questions submitted prior to this call via email. Plea ...